NCT02072213View on ClinicalTrials.gov

A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Healthy
Interventions
DRUG

GL2702 GLARS-NF1

0.4mg once a day

DRUG

Omix Ocas

0.4mg once a day

Trial Locations (1)

561-712

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

GL Pharm Tech Corporation

INDUSTRY